- Previous Close
61.20 - Open
63.20 - Bid 61.15 x --
- Ask 63.90 x --
- Day's Range
62.50 - 63.35 - 52 Week Range
34.00 - 65.25 - Volume
60 - Avg. Volume
3 - Market Cap (intraday)
2.866B - Beta (5Y Monthly) -2.29
- PE Ratio (TTM)
-- - EPS (TTM)
-3.97 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
soleno.lifeRecent News: 6XC.F
View MorePerformance Overview: 6XC.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6XC.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6XC.F
View MoreValuation Measures
Market Cap
2.80B
Enterprise Value
2.58B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
12.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.06%
Return on Equity (ttm)
-87.35%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-175.85M
Diluted EPS (ttm)
-3.97
Balance Sheet and Cash Flow
Total Cash (mrq)
291.44M
Total Debt/Equity (mrq)
21.55%
Levered Free Cash Flow (ttm)
-7.47M